Hawaii 2025 Regular Session

Hawaii House Bill HB562 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	HOUSE OF REPRESENTATIVES H.B. NO. 562 THIRTY-THIRD LEGISLATURE, 2025 STATE OF HAWAII A BILL FOR AN ACT relating to consumer protection. BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
2	2
3	3	HOUSE OF REPRESENTATIVES H.B. NO. 562
4	4	THIRTY-THIRD LEGISLATURE, 2025
5	5	STATE OF HAWAII
6	6
7	7	HOUSE OF REPRESENTATIVES
8	8
9	9	H.B. NO.
10	10
11	11	562
12	12
13	13	THIRTY-THIRD LEGISLATURE, 2025
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29
30	30
31	31	A BILL FOR AN ACT
32	32
33	33
34	34
35	35
36	36
37	37	relating to consumer protection.
38	38
39	39
40	40
41	41
42	42
43	43	BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:
44	44
45	45
46	46
47	47	SECTION 1. The legislature finds that the federal 340B drug pricing program is essential for providing Hawaii's low‑income and uninsured populations with access to healthcare and medications. The federal program requires drug manufacturers to offer significant discounts on outpatient medications to eligible nonprofit hospitals and safety net providers, rural hospitals, community health centers, and Native Hawaiian health centers. The legislature further finds that the 340B drug pricing program helps healthcare providers stretch limited resources, allowing hospitals to reinvest savings into essential community benefits. These benefits include financial assistance for low‑income patients, free wellness visits, screenings, vaccinations, transportation to appointments, health education classes, and workforce development programs. In Hawaii, the drug pricing program also helps support unique services, like the integration of Native Hawaiian health practices into patient care. The legislature recognizes that, despite the importance of the drug pricing program, drug manufacturers have consistently tried to undermine its benefits. Since 2020, some drug manufacturers have limited the ability of 340B entities to prescribe drugs through contract pharmacies. This is an unfair practice that creates a barrier to health care, especially for patients in rural areas, where many hospitals do not have in‑house pharmacies. More than eighty per cent of rural 340B hospitals nationwide rely on contract pharmacies to dispense medications to patients who might otherwise go without critically needed treatments. The legislature notes that contract pharmacies are particularly crucial in Hawaii, where geographic isolation makes it difficult for many residents to access medications. Partnering with contract pharmacies in the State's rural communities allows hospitals, federally qualified health centers and federal Ryan White program participants to ensure that their patients receive their prescribed medications without needing to travel long distances. Additionally, the partnerships provide Hawaii's patients access to some specialty drugs that are only available through specific pharmacy channels. The legislature believes that the restrictions imposed by drug manufacturers on contract pharmacy partnerships not only limit patients' access to affordable medications but also jeopardize the financial status of critical healthcare providers. Hospitals, federally qualified health centers, and federal Ryan White program participants rely on the opportunity to reinvest in their operations the difference between the 340B discounted drug price and the amount reimbursed by insurance. Without access to contract pharmacies, hospitals face reduced savings, which could result in cutbacks to essential healthcare programs. Accordingly, the purpose of this Act is to preserve the integrity of the 340B program and prevent unfair practices that are harmful to consumers by: (1) Prohibiting covered entities in the State from entering into contracts with drug manufacturers that limit the covered entities' use of contract pharmacies; (2) Voiding contract provisions that are based on the maximum allowable cost payment model; and (3) Authorizing the attorney general to bring a civil action for violations of this Act. SECTION 2. Chapter 481B, Hawaii Revised Statutes, is amended by adding a new section to part I to be appropriately designated and to read as follows: "§481B- 340B contract pharmacies; maximum allowable cost basis; prohibited. (a) Beginning June 30, 2025: (1) No 340B covered entity in the State shall enter into a contract with a drug manufacturer, wholesale distributor, or an agent or affiliate of a drug manufacturer or wholesale distributor, if provisions of the contract directly or indirectly restrict or prohibit the acquisition of a 340B drug through a contract pharmacy, unless the acquisition of that drug through a contract pharmacy is prohibited by the United States Department of Human Services; and (2) Any provision of a contract entered into for a drug sold based on the maximum allowable cost payment model, where the payment model was in effect on or before June 30, 2025, shall be void. (b) In addition to any other remedy authorized by section 481B-25, the attorney general may bring a civil action on behalf of any person or persons whose rights under this section have been violated, against any person responsible for violating this section. (c) For purposes of this section: "340B covered entity" means an entity that participates in the 340B drug discount program authorized by 42 United States Code section 256b. "340B drug" means a drug dispensed by a pharmacy and purchased by a 340B covered entity through the 340B drug discount program authorized by 42 United States Code section 256b. "Contract pharmacy" means a pharmacy that is not owned or operated by a covered entity but is contracted with to dispense prescription drugs to eligible patients. "Manufacturer" has the same meaning as defined in section 328-112. "Maximum allowable cost" is a payment model for generic drugs that specifies the maximum amount that a pharmacy can be reimbursed for a specific generic drug, regardless of a manufacturer's price. "Pharmacy" has the same meaning as defined in section 461‑1. "Wholesale distributor" has the same meaning as defined in section 328-112." SECTION 3. This Act does not affect rights and duties that matured, penalties that were incurred, and proceedings that were begun before its effective date. SECTION 4. New statutory material is underscored. SECTION 5. This Act shall take effect upon its approval. INTRODUCED BY: _____________________________
48	48
49	49	SECTION 1. The legislature finds that the federal 340B drug pricing program is essential for providing Hawaii's low‑income and uninsured populations with access to healthcare and medications. The federal program requires drug manufacturers to offer significant discounts on outpatient medications to eligible nonprofit hospitals and safety net providers, rural hospitals, community health centers, and Native Hawaiian health centers.
50	50
51	51	The legislature further finds that the 340B drug pricing program helps healthcare providers stretch limited resources, allowing hospitals to reinvest savings into essential community benefits. These benefits include financial assistance for low‑income patients, free wellness visits, screenings, vaccinations, transportation to appointments, health education classes, and workforce development programs. In Hawaii, the drug pricing program also helps support unique services, like the integration of Native Hawaiian health practices into patient care.
52	52
53	53	The legislature recognizes that, despite the importance of the drug pricing program, drug manufacturers have consistently tried to undermine its benefits. Since 2020, some drug manufacturers have limited the ability of 340B entities to prescribe drugs through contract pharmacies. This is an unfair practice that creates a barrier to health care, especially for patients in rural areas, where many hospitals do not have in‑house pharmacies. More than eighty per cent of rural 340B hospitals nationwide rely on contract pharmacies to dispense medications to patients who might otherwise go without critically needed treatments.
54	54
55	55	The legislature notes that contract pharmacies are particularly crucial in Hawaii, where geographic isolation makes it difficult for many residents to access medications. Partnering with contract pharmacies in the State's rural communities allows hospitals, federally qualified health centers and federal Ryan White program participants to ensure that their patients receive their prescribed medications without needing to travel long distances. Additionally, the partnerships provide Hawaii's patients access to some specialty drugs that are only available through specific pharmacy channels.
56	56
57	57	The legislature believes that the restrictions imposed by drug manufacturers on contract pharmacy partnerships not only limit patients' access to affordable medications but also jeopardize the financial status of critical healthcare providers. Hospitals, federally qualified health centers, and federal Ryan White program participants rely on the opportunity to reinvest in their operations the difference between the 340B discounted drug price and the amount reimbursed by insurance. Without access to contract pharmacies, hospitals face reduced savings, which could result in cutbacks to essential healthcare programs.
58	58
59	59	Accordingly, the purpose of this Act is to preserve the integrity of the 340B program and prevent unfair practices that are harmful to consumers by:
60	60
61	61	(1) Prohibiting covered entities in the State from entering into contracts with drug manufacturers that limit the covered entities' use of contract pharmacies;
62	62
63	63	(2) Voiding contract provisions that are based on the maximum allowable cost payment model; and
64	64
65	65	(3) Authorizing the attorney general to bring a civil action for violations of this Act.
66	66
67	67	SECTION 2. Chapter 481B, Hawaii Revised Statutes, is amended by adding a new section to part I to be appropriately designated and to read as follows:
68	68
69	69	"§481B- 340B contract pharmacies; maximum allowable cost basis; prohibited. (a) Beginning June 30, 2025:
70	70
71	71	(1) No 340B covered entity in the State shall enter into a contract with a drug manufacturer, wholesale distributor, or an agent or affiliate of a drug manufacturer or wholesale distributor, if provisions of the contract directly or indirectly restrict or prohibit the acquisition of a 340B drug through a contract pharmacy, unless the acquisition of that drug through a contract pharmacy is prohibited by the United States Department of Human Services; and
72	72
73	73	(2) Any provision of a contract entered into for a drug sold based on the maximum allowable cost payment model, where the payment model was in effect on or before June 30, 2025, shall be void.
74	74
75	75	(b) In addition to any other remedy authorized by section 481B-25, the attorney general may bring a civil action on behalf of any person or persons whose rights under this section have been violated, against any person responsible for violating this section.
76	76
77	77	(c) For purposes of this section:
78	78
79	79	"340B covered entity" means an entity that participates in the 340B drug discount program authorized by 42 United States Code section 256b.
80	80
81	81	"340B drug" means a drug dispensed by a pharmacy and purchased by a 340B covered entity through the 340B drug discount program authorized by 42 United States Code section 256b.
82	82
83	83	"Contract pharmacy" means a pharmacy that is not owned or operated by a covered entity but is contracted with to dispense prescription drugs to eligible patients.
84	84
85	85	"Manufacturer" has the same meaning as defined in section 328-112.
86	86
87	87	"Maximum allowable cost" is a payment model for generic drugs that specifies the maximum amount that a pharmacy can be reimbursed for a specific generic drug, regardless of a manufacturer's price.
88	88
89	89	"Pharmacy" has the same meaning as defined in section 461‑1.
90	90
91	91	"Wholesale distributor" has the same meaning as defined in section 328-112."
92	92
93	93	SECTION 3. This Act does not affect rights and duties that matured, penalties that were incurred, and proceedings that were begun before its effective date.
94	94
95	95	SECTION 4. New statutory material is underscored.
96	96
97	97	SECTION 5. This Act shall take effect upon its approval.
98	98
99	99
100	100
101	101	INTRODUCED BY: _____________________________
102	102
103	103	INTRODUCED BY:
104	104
105	105	_____________________________
106	106
107	107
108	108
109	109
110	110
111	111	Report Title: Consumer Protection; 340B Drug Discount Program; Maximum Allowable Cost Description: Prohibits covered entities in the State from entering into contracts with drug manufacturers that limit the covered entities' use of contract pharmacies. Voids contract provisions for certain drugs if the provisions are based on the maximum allowable cost payment model. Authorizes the attorney general to bring a civil action for violations. The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.
112	112
113	113
114	114
115	115
116	116
117	117	Report Title:
118	118
119	119	Consumer Protection; 340B Drug Discount Program; Maximum Allowable Cost
120	120
121	121
122	122
123	123	Description:
124	124
125	125	Prohibits covered entities in the State from entering into contracts with drug manufacturers that limit the covered entities' use of contract pharmacies. Voids contract provisions for certain drugs if the provisions are based on the maximum allowable cost payment model. Authorizes the attorney general to bring a civil action for violations.
126	126
127	127
128	128
129	129
130	130
131	131
132	132
133	133	The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.